 DUBLIN, Ireland, Dec. 07, 2020 GLOBE NEWSWIRE -- Avadel Pharmaceuticals plc Nasdaq: AVDL, a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, today announced the appointment of Dr. Jennifer Gudeman to the newly formed role of Vice President, Medical and Clinical Affairs, effective immediately. In this role her responsibilities will include overseeing all medical and clinical affairs activities, including the companys lead program, once-nightly FT218. 